Literature DB >> 24976397

μ-δ opioid receptor heteromer-specific signaling in the striatum and hippocampus.

Noufissa Kabli1, Theresa Fan2, Brian F O'Dowd1, Susan R George3.   

Abstract

The μ-δ opioid receptor heteromer activates the pertussis toxin-resistant Gαz GTP-binding protein following stimulation by the δ-agonist deltorphin-II whereas μ- and δ-receptors activate the pertussis toxin-sensitive Gαi3 protein following stimulation by μ- and δ-agonists, respectively. Although the regulation of the μ-δ heteromer is being investigated extensively in vitro, its physiological relevance remains elusive owing to a lack of available molecular tools. We investigated μ-δ heteromer signaling under basal conditions and following prolonged morphine treatment in rodent brain regions highly co-expressing μ- and δ-receptors and Gαz. Deltorphin-II induced Gαz activation in the striatum and hippocampus, demonstrating the presence of μ-δ heteromer signaling in these brain regions. Prolonged morphine treatment, which desensitizes μ- and δ-receptor function, had no effect on μ-δ heteromer signaling in the brain. Our data demonstrate that μ-δ heteromer signaling does not desensitize and is regulated differently from μ- and δ-receptor signaling following prolonged morphine treatment.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brain; GTPγS; Gα(z); Heterooligomer; δ opioid receptor; μ opioid receptor

Mesh:

Substances:

Year:  2014        PMID: 24976397     DOI: 10.1016/j.bbrc.2014.06.099

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

Review 1.  G Protein-Coupled Receptor Heteromers.

Authors:  Ivone Gomes; Mohammed Akli Ayoub; Wakako Fujita; Werner C Jaeger; Kevin D G Pfleger; Lakshmi A Devi
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015-10-22       Impact factor: 13.820

2.  Evaluation of Analgesia, Tolerance, and the Mechanism of Action of Morphine-6-O-Sulfate Across Multiple Pain Modalities in Sprague-Dawley Rats.

Authors:  Jai Shankar K Yadlapalli; Navdeep Dogra; Anqi W Walbaum; William D Wessinger; Paul L Prather; Peter A Crooks; Maxim Dobretsov
Journal:  Anesth Analg       Date:  2017-09       Impact factor: 5.108

3.  Convergent, functionally independent signaling by mu and delta opioid receptors in hippocampal parvalbumin interneurons.

Authors:  Xinyi Jenny He; Janki Patel; Connor E Weiss; Xiang Ma; Brenda L Bloodgood; Matthew R Banghart
Journal:  Elife       Date:  2021-11-17       Impact factor: 8.140

4.  Pharmacogenetics of Addiction Therapy.

Authors:  David P Graham; Mark J Harding; David A Nielsen
Journal:  Methods Mol Biol       Date:  2022

Review 5.  Strategies towards safer opioid analgesics-A review of old and upcoming targets.

Authors:  Balazs R Varga; John M Streicher; Susruta Majumdar
Journal:  Br J Pharmacol       Date:  2021-11-26       Impact factor: 9.473

6.  Activation of µ-δ opioid receptor heteromers inhibits neuropathic pain behavior in rodents.

Authors:  Vinod Tiwari; Shao-Qiu He; Qian Huang; Lingli Liang; Fei Yang; Zhiyong Chen; Vineeta Tiwari; Wakako Fujita; Lakshmi A Devi; Xinzhong Dong; Yun Guan; Srinivasa N Raja
Journal:  Pain       Date:  2020-04       Impact factor: 7.926

Review 7.  Signaling within Allosteric Machines: Signal Transmission Pathways Inside G Protein-Coupled Receptors.

Authors:  Damian Bartuzi; Agnieszka A Kaczor; Dariusz Matosiuk
Journal:  Molecules       Date:  2017-07-15       Impact factor: 4.411

8.  The Balance of MU-Opioid, Dopamine D2 and Adenosine A2A Heteroreceptor Complexes in the Ventral Striatal-Pallidal GABA Antireward Neurons May Have a Significant Role in Morphine and Cocaine Use Disorders.

Authors:  Dasiel O Borroto-Escuela; Karolina Wydra; Ramon Fores-Pons; Lakshmi Vasudevan; Wilber Romero-Fernandez; Małgorzata Frankowska; Luca Ferraro; Sarah Beggiato; Minerva Crespo-Ramirez; Alicia Rivera; Luisa L Rocha; Miguel Perez de la Mora; Christophe Stove; Małgorzata Filip; Kjell Fuxe
Journal:  Front Pharmacol       Date:  2021-03-15       Impact factor: 5.810

9.  Antagonism of the mu-delta opioid receptor heterodimer enhances opioid antinociception by activating Src and calcium/calmodulin-dependent protein kinase II signaling.

Authors:  Attila Keresztes; Keith Olson; Paul Nguyen; Marissa A Lopez-Pier; Ryan Hecksel; Natalie K Barker; Zekun Liu; Victor Hruby; John Konhilas; Paul R Langlais; John M Streicher
Journal:  Pain       Date:  2022-01-01       Impact factor: 6.961

Review 10.  Heteromerization Modulates mu Opioid Receptor Functional Properties in vivo.

Authors:  Muzeyyen Ugur; Lyes Derouiche; Dominique Massotte
Journal:  Front Pharmacol       Date:  2018-11-13       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.